ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2022
Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023.Advances in therapy · 2025Pooled it
- Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.Dermatology and therapy · 2026Article
- Retrospective Real-World Comparison of Adherence, Persistence, Health-Care Utilization, and Costs Among Biologics for Moderate-to-Severe Psoriasis in China.Clinical drug investigation · 2026Article
- Real-world single-centre experience of bimekizumab in patients with psoriasis: a 16-week retrospective observational study.Skin health and disease · 2026Article
- Switching patterns of secukinumab in psoriasis treatment from a Chinese nationwide registry cohort.Chinese medical journal · 2026Article
- Health-related quality of life in patients with psoriasis eligible for biologic therapy in southern Iran via the EQ-5D-5 L and DLQI.Scientific reports · 2026Article
- Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania.Medicina (Kaunas, Lithuania) · 2026Article
- Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.Dermatology and therapy · 2025Article
- Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.American journal of clinical dermatology · 2025Article
- Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics.Archives of dermatological research · 2025Observational
- Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO).Advances in therapy · 2025Observational
- Switching biologics in psoriasis in real life settings: a single center experience.Archives of dermatological research · 2024Article
- Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry.Dermatology and therapy · 2024Article
- Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).Dermatology and therapy · 2024Article
- Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China.Dermatology and therapy · 2024Article
- A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians.Dermatology and therapy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundBiologics are the cornerstone of treatment of patients with moderate-to-severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time.
objectivesThe main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents.
methodsWe included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate-to-severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra-class - i.e. within the same therapeutic class - vs. inter-class) in patients switching from a TNF-alpha inhibitor using multivariate logistic regression.
resultsA total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF-alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL-17 inhibitor. Patients switching from a first-line TNF-alpha inhibitor before 2016 were more likely to switch to another TNF-alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF-alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab.
conclusionThis study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL-17 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.